416 related articles for article (PubMed ID: 32572825)
1. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
2. Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence.
Ciani O; Grigore B; Taylor RS
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):44-72. PubMed ID: 35608044
[TBL] [Abstract][Full Text] [Related]
3. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
4. Use of Surrogate end points in HTA.
Mangiapane S; Velasco Garrido M
GMS Health Technol Assess; 2009 Aug; 5():Doc12. PubMed ID: 21289899
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
6. Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.
Ciani O; Grigore B; Blommestein H; de Groot S; Möllenkamp M; Rabbe S; Daubner-Bendes R; Taylor RS
Med Decis Making; 2021 May; 41(4):439-452. PubMed ID: 33719711
[TBL] [Abstract][Full Text] [Related]
7. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
8. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
Taylor RS; Elston J
Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
[TBL] [Abstract][Full Text] [Related]
9. Surrogate outcomes in health technology assessment: an international comparison.
Velasco Garrido M; Mangiapane S
Int J Technol Assess Health Care; 2009 Jul; 25(3):315-22. PubMed ID: 19619350
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment of medical devices: a survey of non-European union agencies.
Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
[TBL] [Abstract][Full Text] [Related]
11. Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe.
Oortwijn W; Jansen M; Baltussen R
Int J Health Policy Manag; 2020 Jan; 9(1):27-33. PubMed ID: 31902192
[TBL] [Abstract][Full Text] [Related]
12. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
14. HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations.
Hoxhaj I; Castagna C; Calabrò GE; Boccia S
Front Public Health; 2022; 10():795763. PubMed ID: 35223734
[TBL] [Abstract][Full Text] [Related]
15. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
16. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
[TBL] [Abstract][Full Text] [Related]
17. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
[TBL] [Abstract][Full Text] [Related]
18. Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.
Weir CJ; Taylor RS
Pharm Stat; 2022 Jul; 21(4):740-756. PubMed ID: 35819121
[TBL] [Abstract][Full Text] [Related]
19. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
Mittermayer R; Huić M; Mestrović J
Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
[TBL] [Abstract][Full Text] [Related]
20. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
